Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

700 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-09

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19

NCT04493359

Covid19 Angiotensin II Receptor Antagonist Adverse Reaction

TERMINATED PHASE2/PHASE3

ARB, ACEi, DRi Effects on COVID-19 Course Disease

NCT04364984

Hypertension COVID-19

COMPLETED

The COVID-RASi Trial (COVID-19)

NCT04591210

COVID-19 Cardiovascular Diseases

ACTIVE_NOT_RECRUITING PHASE3

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19

NCT05398731

COVID-19 Pneumonia

UNKNOWN

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

NCT04606563

Covid19 SARS-CoV Infection

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Several interactions by pre-existing therapies for chronic diseases, therapies used by SARS-CoV2 infection generate doubts about risks and benefits. Among these situations in which the current data indicate a situation of equipoise would be about the maintenance or suspension of ACEI / BRA in patients with SARS-CoV2 infection. Increasing the expression of ECA-2 could increase the binding to the virus, however, there are studies that indicate this increase in ECA-2 could be protective. So far, there is no clinical evidence to confirm any of the theories, and this question can only be clarified through a randomized clinical trial.

The objective is to evaluate the impact of the suspension of the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (BRA) on the length of hospital stay and on the mortality of patients with SARS-CoV2 infection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corona Virus Infection COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Group Type OTHER

Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Intervention Type OTHER

Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Group 2

Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Group Type OTHER

Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Intervention Type OTHER

Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients hospitalized with COVID-19 diagnosis using ACE inhibitors or blockers of angiotensin receptor;
* Patients ≥ 18 years old;
* Maximum use of 3 antihypertensive drugs;
* Sign the consent form.

Exclusion Criteria

* Severe evolution with orotracheal intubation, use of mechanical ventilation and / or hemodynamic instability in the first 24 hours until COVID-19 diagnosis confirmation;
* Patients hospitalized per decompensated congestive heart failure in the last 12 months;
* Use of Sacubitril/Valsartan
* Pregnancy
* Recent acute renal failure and shock

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No